Impact of COVID-19 on Quality of Life in Long-Term Advanced Rectal Cancer Survivors.

COVID-19 pandemic quality of life radiochemotherapy rectal cancer

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
08 Jul 2023
Historique:
received: 03 05 2023
revised: 28 06 2023
accepted: 06 07 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Colorectal cancer remains one of the most commonly diagnosed cancers. Advanced rectal cancer patients receive neoadjuvant radiochemotherapy as well as surgery and suffer from reduced health-related quality of life due to various side effects. We were interested in the role of the COVID-19 pandemic and how it affected those patients' quality of life. A total of 489 advanced rectal cancer patients from the University Hospital Erlangen in Germany were surveyed between May 2010 and March 2022 and asked to fill out the EORTC QLQ-C30 and QLQ-CR38 questionnaires over eight different time points: at the beginning, during and after radiochemotherapy, right before surgery, and in yearly intervals after surgery for up to four years. Answers were converted to scores to compare the COVID-19 period to the time before March 2020, focusing on the follow-ups, the developments over time-including by sex and age-and the influence of the TNM cT-stage. Overall, a trend of impaired functional and symptom scores was found across all surveys with few significances (body image -10.6 percentage points (pp) after one year; defecation problems +13.5 pp, insomnia +10.2 pp and weight loss +9.8 pp after three years; defecation problems +11.3 pp after four years). cT4-stage patients lost significantly more weight than their cT1-3-stage counterparts (+10.7 to 13.7 pp). Further studies should be conducted to find possible causes and develop countermeasures for future major infectious diseases.

Identifiants

pubmed: 37510423
pii: healthcare11141981
doi: 10.3390/healthcare11141981
pmc: PMC10379628
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Radiother Oncol. 2013 Aug;108(2):326-30
pubmed: 24021342
Strahlenther Onkol. 2023 Mar;199(3):268-277
pubmed: 36564569
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Gastrointest Cancer. 2022 Jun;53(2):502-510
pubmed: 35061209
Int J Colorectal Dis. 2018 Jun;33(6):683-694
pubmed: 29589108
Cancers (Basel). 2021 Dec 29;14(1):
pubmed: 35008311
BMC Public Health. 2020 Nov 6;20(1):1596
pubmed: 33153441
Support Care Cancer. 2021 Nov;29(11):6297-6304
pubmed: 33860361
Arch Womens Ment Health. 2020 Dec;23(6):741-748
pubmed: 33263142
Infect Drug Resist. 2021 Sep 17;14:3809-3816
pubmed: 34557004
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Sleep Med. 2021 Nov;87:38-45
pubmed: 34508986
BMC Cancer. 2013 Jan 03;13:6
pubmed: 23281602
Biomed Res Int. 2018 Apr 15;2018:5471054
pubmed: 29850533
Int J Environ Res Public Health. 2021 Oct 30;18(21):
pubmed: 34769956
J Clin Epidemiol. 2015 Mar;68(3):266-78
pubmed: 25455838
Psychooncology. 2020 Sep;29(9):1377-1379
pubmed: 32779778
Acta Oncol. 2021 Jan;60(1):4-12
pubmed: 33031010
Dtsch Arztebl Int. 2022 Aug 22;119(33-34):570-580
pubmed: 35791271
Acta Oncol. 2021 Jul;60(7):872-880
pubmed: 33764267
Clin Cancer Res. 2007 Jun 1;13(11):3264-8
pubmed: 17545532
Gerontologist. 2021 Feb 23;61(2):228-239
pubmed: 33320191
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
J Gerontol B Psychol Sci Soc Sci. 2021 Jan 18;76(2):e45-e48
pubmed: 32697834
J Cachexia Sarcopenia Muscle. 2021 Feb;12(1):9-13
pubmed: 33382211
Healthcare (Basel). 2022 Aug 11;10(8):
pubmed: 36011170
Dtsch Med Wochenschr. 2021 Jan;146(2):e11-e20
pubmed: 33260231
Sci Rep. 2021 Aug 12;11(1):16443
pubmed: 34385482
Eur J Cancer. 2003 Mar;39(5):587-94
pubmed: 12628837
J Cancer Surviv. 2020 Aug;14(4):504-517
pubmed: 32162194
Strahlenther Onkol. 2022 Dec;198(12):1053-1061
pubmed: 35467099
Psychiatry Res. 2020 Nov;293:113462
pubmed: 32987222
Am J Prev Med. 2019 Jan;56(1):141-146
pubmed: 30573142

Auteurs

Daniel Blasko (D)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Claudia Schweizer (C)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Tim Fitz (T)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Christoph Schröter (C)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Christopher Sörgel (C)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Annett Kallies (A)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Rainer Fietkau (R)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Luitpold Valentin Distel (LV)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.

Classifications MeSH